Clinical Application of Near-infrared Whole Body Heat Shock Multimodal Technique in Treatment of Castration-resistant Prostate Cancer

In this study, we propose to use the combination of ET-SPACE NIR irradiation whole-body thermal stimulation, ICI (Tislelizumab), and RTK inhibitor (Anlotinib) in the multimodal treatment of CRPC.

Trial Details

NCT ID
NCT06249750
Phase
PHASE2
Sponsor
Pengyuan Liu
Status
RECRUITING
Cancer Type
Castration-Resistant (CRPC) Prostate Cancer
Interventions
  • Immunotherapy
  • Targeted therapy
  • Hyperthermia
Locations (sample)
  • Hangzhou, Zhejiang, China|30.29365,120.16142

Key Eligibility Criteria

  • Histopathologically confirmed diagnosis of PC and clinically confirmed diagnosis of CRPC;
  • Complete and reliable medical history and medical records;
  • No other primary tumors except CRPC;
  • Blood tests, liver function, renal function and electrocardiogram are basically normal;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Castration-Resistant (CRPC) Prostate Cancer Trials on Trialify →